Management of Bladder Cancer

A Comprehensive Text With Clinical Scenarios
Springer (Verlag)
  • erschienen am 17. November 2014
  • |
  • XX, 479 Seiten
E-Book | PDF mit Wasserzeichen-DRM | Systemvoraussetzungen
978-1-4939-1881-2 (ISBN)

Management of bladder cancer provides a single, comprehensive reference source that incorporates all the latest information regarding bladder cancer. The text covers epidemiology and natural history of bladder cancer as well as latest findings regarding the genetics and molecular biology of the disease. Diagnostic and staging evaluation of both non-muscle invasive and invasive bladder cancer is discussed. The text incorporates chapters summarizing new findings regarding markers for the diagnosis of bladder cancer and new diagnostic techniques to enhance traditional methods such as cystoscopy. Risk stratified treatment of non muscle invasive bladder cancer including various approaches to intravesical therapy are reviewed. Current guideline based approaches to management and new data regarding diagnosis and prognostication of muscle invasive bladder cancer is analyzed and summarized. The application of chemotherapy for muscle invasive and advanced disease is discussed and the evidence based application of multimodality therapy highlighted. Finally, gaps in current knowledge and areas for future research are highlighted. Ongoing important clinical trials which could imminently yield significant new knowledge is discussed.

Authored by experts in their respective fields, Management of Bladder Cancer will serve as a easy and complete reference source for clinicians, researchers, individuals in training, allied health professionals and medical students in the fields of Urology, Medical Oncology, Radiation Oncology, Basic and Translational Science and Epidemiology.

  • Englisch
  • NY
  • |
  • USA
  • 68
  • |
  • 6 s/w Abbildungen, 68 farbige Abbildungen
  • |
  • 6 schwarz-weiße und 68 farbige Abbildungen, Bibliographie
  • 20,57 MB
978-1-4939-1881-2 (9781493918812)
weitere Ausgaben werden ermittelt
Badrinath R. Konety, MD, MBA, FACSProfessor and Chair, Dept. of UrologyDougherty Family Chair in Urologic OncologyAssociate Director for Clinical Affairs, Masonic Cancer CenterUniversity of MinnesotaMMC 394, 420 Delaware StMinneapolis MN 55455, USA Sam S. Chang, MD, FACSProfessor of Urologic SurgeryPatricia and Rodes Hart Chair of Urologic SurgeryDepartment of Urologic SurgeryVanderbilt University Medical CenterMCN A 1302, VUMCNashville, TN 37232, USA
I. GENERAL CONCEPTS 1. Epidemiology and natural historyEdward Messing and Emil Scosyrev 2. Screening for Bladder CancerLaura-Maria Krabbe, Robert S. Svatek and Yair Lotan 3. Pathology and Staging: Histopathology and CytopathologyAmber Mackey, Farnaz Hasteh and Donna E. Hansel 4. Pathology and Staging: Genetics and Molecular BiologySean McAdams and Michael C. Risk 5. Imaging in Localized and Advanced Bladder CancerTimothy Kim, Joshua G. Griffin, Jeffrey M. Holzbeierlein and Wade J. Sexton 6. New Imaging Techniques in Staging of Urothelial Carcinoma of the BladderRamdev Konijeti and Adam S. Kibel 7. Socioeconomic issues and improved quality of careJohn L. Gore 8. Quality of life measuresChristopher B. Anderson, David F. Penson and Daniel A. Barocas 9. Prognostication and risk assessmentLuis Alex Kluth, Bernie Bochner and Shahrokh F. Shariat 10. Clinical trials and emerging therapeutic strategies in bladder cancerRichard M. Bambury, Robert B. Sims and Jonathan E. Rosenberg II. NON MUSCLE INVASIVE BLADDER CANCER 11. Improved diagnostic techniquesSeth P. Lerner and Alvin C. Goh 12. Clinical scenario: Microscopic hematuria and atypical cytology in a 68 year old man with normal upper tract imagingChristopher S. Gomez, Mark S. Soloway, Jorge Caso, Claudia P. Rojas and Merce Jorda 13. Localized surgical therapy and surveillanceManish I. Patel and Paul D. Sved 14. Clinical Scenario: Initial high grade Ta tumorJose L. Dominguez-Escrig and Eduardo Solsona Narbón 15. Clinical Scenario: Recurrent Ta tumorJoseph A. Gillespie and Michael A. O'Donnell 16. Clinical Scenario: Rapidly growing, high volume, low grade Ta tumorJames S. Rosoff and Thomas A. Keane 17. Clinical Scenario: Low grade T1 tumorJ. Alfred Witjes and Florine W.M. Schlatmann 18. Intravesical therapyJennifer J. Ahn and James M. McKiernan 19. Clinical Scenario: Initial CISSima P. Porten and Colin P. Dinney 20. Management of BCG Recurrent Bladder CancerTracy M. Downs, Daniel J. Lee and Douglass S. Scherr 21. Clinical Scenario: Persistent CIS and HIGH Grade Ta Bladder Cancer after BCGMaurizio Brausi 22. Clinical Scenario: Presentation and Management of Significant Side Effects from Bacillus Calmette-Guérin Bladder InstillationDonald L. Lamm and Nilay M. Gandhi 23. Guideline-based management of non-muscle invasive bladder cancer: comparison of the AUA, EAU, ICUD and NCCN guidelinesJeffrey C. Bassett, John D. Seigne and Peter E. Clark III. MUSCLE INVASIVE BLADDER CANCER 24. Open Radical CystectomyJ. Joy Lee, Dipen J. Parekh and Mark L. Gonzalgo 25. Robotic cystectomyMichael Woods, Raj Pruthi and Erik P. Castle 26. Clinical Scenario: T2 bladder tumorRichard E. Hautmann 27. Urinary Diversion: Open and robotic techniquesNorm D. Smith, Gary D. Steinberg and Cheryl T. Lee 28. ChemoradiotherapyChristian Weiss and Claus Rödel 29. Clinical Scenario: 53 year-old man with a solitary, 2 cm, high-grade T2 tumor and focal CIS in the bladder dome who wants bladder preservationAlbert J. Chang, Maurice Marcel Garcia and Mack Roach III 30. Management of Bladder Cancer, role of chemotherapy and controversies surrounding its applicationGautam Jha, Guru Sonpavde and Zeeshan Ahmad 31. Clinical Scenario: Large volume, non metastatic T2 bladder tumorChad R. Ritch and Michael S. Cookson 32. The role of pelvic lymphadenectomy at the time of radical cystectomy for bladder cancerSamuel D. Kaffenberger, Todd M. Morgan and Anne K. Schuckman 33. Clinical Scenario: Unexpected positive nodes at radical cystectomyChristian Thomas and Joachim W. Thüroff 34. Surveillance and monitoringDaniel J. Canter, Joseph Zabell, Stephen A. Boorjian and Christopher J. Weight 35. Clinical Scenario: The Role of Perioperative ChemotherapyEila C. Skinner 36. Management of Bladder Cancer with Pelvic Nodal Metastases After Complete Response to ChemotherapyAdam C. Reese and Mark P. Schoenberg 37. Guideline based management muscle-invasive bladder cancer: NCCN, ICUD and EAUAmanda N. Calhoun and Kamal S. Pohar

Dateiformat: PDF
Kopierschutz: Wasserzeichen-DRM (Digital Rights Management)


Computer (Windows; MacOS X; Linux): Verwenden Sie zum Lesen die kostenlose Software Adobe Reader, Adobe Digital Editions oder einen anderen PDF-Viewer Ihrer Wahl (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie die kostenlose App Adobe Digital Editions oder eine andere Lese-App für E-Books (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nur bedingt: Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Wasserzeichen-DRM wird hier ein "weicher" Kopierschutz verwendet. Daher ist technisch zwar alles möglich - sogar eine unzulässige Weitergabe. Aber an sichtbaren und unsichtbaren Stellen wird der Käufer des E-Books als Wasserzeichen hinterlegt, sodass im Falle eines Missbrauchs die Spur zurückverfolgt werden kann.

Weitere Informationen finden Sie in unserer E-Book Hilfe.

Download (sofort verfügbar)

128,39 €
inkl. 7% MwSt.
Download / Einzel-Lizenz
PDF mit Wasserzeichen-DRM
siehe Systemvoraussetzungen
E-Book bestellen